Clinical Trial News and Research

RSS

CytRx sells global rights of molecular chaperone assets to Orphazyme

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, Denmark-based Orphazyme ApS.

17 May 2011

PGT, Quintiles collaborate to bring genomic testing into mainstream drug development

Quintiles, the world's leading biopharmaceutical services company, and Population Genetics Technologies Ltd., creator of innovative solutions to reduce the costs and complexity of large-scale genomic testing and enable correlations with clinical outcomes, today announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.

17 May 2011

Linezolid more effective than vancomycin in treating ventilated patients with MRSA pneumonia: Study

The antibiotic linezolid may be more effective than vancomycin in treating ventilated patients who develop methicillin-resistant Staphylococcus aureus (MRSA) pneumonia as a result of their ventilation, according to a study conducted globally by American and French researchers.

17 May 2011

Histogenics announces acquisition of ProChon Biotech

Histogenics Corporation, a privately held regenerative medicine company, announced today that it has acquired ProChon Biotech, Ltd. in a stock-for-stock exchange.

17 May 2011

Gene variant linked to infertility in women

A variation in a gene involved in regulating cholesterol in the bloodstream also appears to affect progesterone production in women, making it a likely culprit in a substantial number of cases of their infertility, a new study from Johns Hopkins researchers suggests.

16 May 2011

InVivo Therapeutics reports net loss of $1,278,000 for first quarter 2011

InVivo Therapeutics, a medical device company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today reported financial results for the first quarter 2011.

16 May 2011

Study: HIV treatment drugs slash transmission risk

AIDS researchers offered evidence backing up the long-standing idea that people infected with HIV who are being treated are much less likely to transmit the virus than those who are not on drugs. This finding is being hailed as a breakthrough.

16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Early HIV treatment can reduce transmission risk by 96%, preliminary study results show

Preliminary results from a multicountry clinical trial, sponsored by the National Institute for Allergy and Infectious Diseases (NIAID), show that HIV-positive people who take combination antiretroviral therapy (ART) can reduce the risk of transmitting the virus to their HIV-negative partners by 96 percent, U.S. researchers announced on Thursday " in what is being hailed as a breakthrough in HIV prevention," the Los Angeles Times reports.

16 May 2011

New autism research findings presented at 10th annual IMFAR

Much about autism is unknown, but researchers from the University of Rochester Medical Center (URMC) are working to learn more about the neurodevelopmental disorder and its most effective treatments. A team of researchers from URMC joins researchers from across the world in San Diego this week for the 10th annual International Meeting for Autism Research (IMFAR).

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Early treatment of HIV makes infection transmission less likely: Study

“It's a game-changer,” Michel Sidibe, executive director of UNAIDS, said. “I am completely amazed.” It was noted that anti-HIV drugs called antiretroviral drugs can suppress HIV in an infected patient and also help to prevent its spread through intercourse, he said. He predicted a rethink of the strategies that have evolved since the first cases of AIDS were recorded in June 1981. “The implications are multiple,” said Mr Sidibe. “However, money will be the major challenge.”

15 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

Pro-Pharmaceuticals reports net loss of $2.7 million for first quarter 2011

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the first quarter, ended March 31, 2011.

13 May 2011

Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

13 May 2011

PROTECT II study data in high-risk percutaneous coronary intervention to be presented at EuroPCR

Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced that data from the PROTECT II study will be presented by Jeffrey W. Moses, M.D., Director of Interventional Services at NewYork-Presbyterian Hospital/Columbia University - Cornell Medical Center, during the late-breaking registries and clinical trial update session at EuroPCR 2011 in Paris.

13 May 2011

Early antiretroviral treatment can halt HIV spread in couples

A research study led by the University of North Carolina at Chapel Hill has made a major discovery in the effort to halt the spread of HIV, the virus that causes AIDS.

13 May 2011

Researchers identify miRNA in blood serum of lung cancer patients

Researchers have identified characteristic patterns of molecules called microRNA in the blood of people with lung cancer that might reveal both the presence and aggressiveness of the disease, and perhaps who is at risk of developing it.

13 May 2011

PLC Systems to showcase RenalGuard at 2011 EAPCI annual meeting

PLC Systems Inc., a company focused on innovative medical device technologies, today announced it will demonstrate its innovative new product, RenalGuard, at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions.

12 May 2011